Zimmer Biomet Holdings (XSWX:ZBH) Tariff Resilience Score: 8/10 (As of Jul. 02, 2026)


XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
65 GF Score
Price CHF69.50
GF Value CHF104.19
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Tariff Resilience Score?

Zimmer Biomet Holdings XSWX:ZBH 65 Tariff Resilience Score is 8 as of Jul. 02, 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 65/100 and a GF Value™ of CHF104.19 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 99.64% on this metric.

Zimmer Biomet Holdings has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Zimmer Biomet Holdings has Zimmer Biomet's global operations in medical devices face some tariff risks, but strong pricing power and critical healthcare demand provide resilience. Historical impacts have been minimal due to strategic supply chain management.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zimmer Biomet Holdings might have Highly Resilient.

Zimmer Biomet Holdings  (XSWX:ZBH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zimmer Biomet Holdings Tariff Resilience Score Related Terms

XSWX:ZBH vs STE, PEN, GMED: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Tariff Resilience Score falls into.


XSWX:ZBH
65GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Tariff Resilience Score of 8 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Zimmer Biomet Holdings ranks #3 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is Zimmer Biomet Holdings' Tariff Resilience Score too high?
Zimmer Biomet Holdings' current Tariff Resilience Score is 8. Based on the distribution chart, Zimmer Biomet Holdings ranks #3 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Tariff Resilience Score compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #3 out of 837 companies for Tariff Resilience Score. This places Zimmer Biomet Holdings in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Zimmer Biomet Holdings's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF104.19, compared to a current price of CHF69.50 — trading 33.3% below its estimated fair value. The current Tariff Resilience Score is 8. Zimmer Biomet Holdings' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Tariff Resilience Score is 8 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF69.50 is trading 33.3% below its estimated GF Value™ of CHF104.19. GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.

Key valuation signals for XSWX:ZBH:

  • Tariff Resilience Score: 8
  • GF Value™: CHF104.19 vs. price of CHF69.50 (33.3% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
65GF Score

Get the complete analysis for XSWX:ZBH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF69.50
Price
CHF104.19
GF Value